For how we live.
The phase 3 RT CHARM trial found a three-week course of radiation after mastectomy was no worse than the standard five-week course for reconstruction complications, at 12.3% versus 10.2%.
In 221 male childhood-cancer survivors, FSH levels during puberty tracked adult testicular function. Radiotherapy damage persisted into adulthood, while alkylating-chemotherapy effects often recovered.
In the phase 3 SWOG/NRG S1914 trial, adding atezolizumab to stereotactic radiotherapy for high-risk, inoperable early lung cancer left 2-year survival at 82% in both groups and caused more serious side effects.
In the French GETUG AFU 18 trial an 80 Gy dose beat the standard 70 Gy on 10-year progression-free survival (83.6% vs 72.2%), but the advantage at the prespecified 5-year mark was far smaller.
A national survey finds treatment volumes above 2021 levels and linear accelerators replacing cobalt-60 units. Nearly every department still using cobalt says replacing the source is now unfeasible.